Cancer risk escalates in children born to epileptic mothers on high-dose folic acid

Written By :  Dr.Niharika Harsha B
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-10-04 14:00 GMT   |   Update On 2022-10-04 14:00 GMT

A new investigation found that there is an increased risk of childhood cancer in children who are born to epileptic mothers taking high-dose folic acid. The study was published in JAMA Neurology. Epileptic women who are on antiseizure medication are prescribed high-dose folic acid before and during pregnancy to avoid fetal congenital anomalies. Folic acid is very essential for the synthesis...

Login or Register to read the full article

A new investigation found that there is an increased risk of childhood cancer in children who are born to epileptic mothers taking high-dose folic acid. The study was published in JAMA Neurology

Epileptic women who are on antiseizure medication are prescribed high-dose folic acid before and during pregnancy to avoid fetal congenital anomalies. Folic acid is very essential for the synthesis and repair of nucleic acids. High levels of folic acid can induce oxidative stress and lead to the development of neoplastic lesions. But there is uncertainty if prenatal exposure to high-dose folic acid increases the risk of childhood cancer. Hence researchers conducted a study to assess the association of high dose folic acid supplementation with childhood cancer. 

An Observational cohort study was conducted with nationwide registers in Denmark, Norway, and Sweden from 1997 to 2017. Data was collected by identifying mother-child pairs from medical birth registers and linking the information from the patient, prescription, and cancer registers, along with the sociodemographic information from statistical agencies, and categorized by a maternal diagnosis of epilepsy. After the exclusion of 1,26,711 children because of stillbirth or missing or erroneous values on important covariates, 3,379,171 children were taken as the study population. Maternal prescription fills for high-dose folic acid tablets of ≥1 mg daily between 90 days before pregnancy started and birth were considered. The main outcome was the first onset of childhood cancer at an age younger than 20 years. Cox proportional hazards models were used to calculate adjusted hazard ratios with corresponding 95% CIs, adjusted for potential confounders. Cumulative incidence at the age of 20 years was used as a measure of absolute risk. 

Key findings: 

  • The median age at the end of follow-up in the study population of 3 379 171 children was 7.3 years.
  • Among the 27 784 children born to mothers with epilepsy, 5934 (21.4%) were exposed to high-dose folic acid at a mean dose of 4.3 mg. 
  • There were 18 exposed cancer cases compared with 29 unexposed, producing an adjusted hazard ratio of 2.7, absolute risk if exposed of 1.4%, and absolute risk if unexposed of 0.6%.
  • In children of mothers without epilepsy, 46 646 (1.4%) were exposed to high-dose folic acid at a mean dose of 2.9 mg, with 69 exposed and 4927 unexposed cancer cases and an adjusted hazard ratio of 1.1.
  • There was no association between children born to mothers with epilepsy who were prenatally exposed to antiseizure medications, but not high-dose folic acid, and an increased risk of cancer. 

Take home points: 

The study was carried out to find the cancer risk in children born to mothers taking antiseizure medication and high doses of folic acid. The incidence rate of cancer in children of mothers with epilepsy who were prescribed high-dose folic acid was 42.5 per 100 000 person-years compared with 18.4 per 100 000 person-years in children of mothers with epilepsy who were not prescribed. Prenatal exposure to high-dose folic acid was associated with an increased risk of childhood cancer in children born to epileptic mothers taking antiseizure medication.

Further reading: doi:10.1001/jamaneurol.2022.2977

Vegrim HM, Dreier JW, Alvestad S, et al. Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy. JAMA Neurol. Published online September 26, 2022. 

Tags:    
Article Source : JAMA Neurology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News